Prison-based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: A modelling study.
elimination
hepatitis C virus
incarceration
people who inject drugs
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
07
09
2022
received:
20
06
2022
accepted:
25
10
2022
pubmed:
29
10
2022
medline:
25
2
2023
entrez:
28
10
2022
Statut:
ppublish
Résumé
People who inject drugs (PWID) experience high incarceration rates which are associated with increased hepatitis C virus (HCV) transmission risk. We assess the importance of prison-based interventions for achieving HCV elimination among PWID in New South Wales (NSW), Australia. A model of incarceration and HCV transmission among PWID was calibrated in a Bayesian framework to epidemiological and incarceration data from NSW, incorporating elevated HCV acquisition risk among recently released PWID. We projected the contribution of differences in transmission risk during/following incarceration to HCV transmission over 2020-2029. We estimated the past and potential future impact of prison-based opioid agonist therapy (OAT; ~33% coverage) and HCV treatment (1500 treatments in 2019 with 32.9%-83.3% among PWID) on HCV transmission. We estimated the time until HCV incidence reduces by 80% (WHO elimination target) compared to 2016 levels with or without prison-based interventions. Over 2020-2029, incarceration will contribute 23.0% (17.9-30.5) of new HCV infections. If prison-based interventions had not been implemented since 2010, HCV incidence in 2020 would have been 29.7% (95% credibility interval: 22.4-36.1) higher. If current prison and community HCV treatment rates continue, there is an 98.8% probability that elimination targets will be achieved by 2030, with this decreasing to 10.1% without current prison-based interventions. Existing prison-based interventions in NSW are critical components of strategies to reduce HCV incidence among PWID. Prison-based interventions are likely to be pivotal for achieving HCV elimination targets among PWID by 2030.
Sections du résumé
BACKGROUND & AIMS
People who inject drugs (PWID) experience high incarceration rates which are associated with increased hepatitis C virus (HCV) transmission risk. We assess the importance of prison-based interventions for achieving HCV elimination among PWID in New South Wales (NSW), Australia.
METHODS
A model of incarceration and HCV transmission among PWID was calibrated in a Bayesian framework to epidemiological and incarceration data from NSW, incorporating elevated HCV acquisition risk among recently released PWID. We projected the contribution of differences in transmission risk during/following incarceration to HCV transmission over 2020-2029. We estimated the past and potential future impact of prison-based opioid agonist therapy (OAT; ~33% coverage) and HCV treatment (1500 treatments in 2019 with 32.9%-83.3% among PWID) on HCV transmission. We estimated the time until HCV incidence reduces by 80% (WHO elimination target) compared to 2016 levels with or without prison-based interventions.
RESULTS
Over 2020-2029, incarceration will contribute 23.0% (17.9-30.5) of new HCV infections. If prison-based interventions had not been implemented since 2010, HCV incidence in 2020 would have been 29.7% (95% credibility interval: 22.4-36.1) higher. If current prison and community HCV treatment rates continue, there is an 98.8% probability that elimination targets will be achieved by 2030, with this decreasing to 10.1% without current prison-based interventions.
CONCLUSIONS
Existing prison-based interventions in NSW are critical components of strategies to reduce HCV incidence among PWID. Prison-based interventions are likely to be pivotal for achieving HCV elimination targets among PWID by 2030.
Identifiants
pubmed: 36305315
doi: 10.1111/liv.15469
pmc: PMC10308445
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
569-579Subventions
Organisme : Medical Research Council
ID : MR/N00616X/1
Pays : United Kingdom
Informations de copyright
© 2022 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Med J Aust. 2020 May;212(8):365-370
pubmed: 32167586
Drug Alcohol Depend. 2015 Sep 1;154:208-13
pubmed: 26154480
PLoS One. 2015 Nov 12;10(11):e0142770
pubmed: 26562516
J Viral Hepat. 2019 Jan;26(1):83-92
pubmed: 30267593
Addiction. 2020 May;115(5):901-913
pubmed: 31633853
Lancet Gastroenterol Hepatol. 2019 Jun;4(6):435-444
pubmed: 30981685
Cochrane Database Syst Rev. 2017 Sep 18;9:CD012021
pubmed: 28922449
Addiction. 2014 Aug;109(8):1306-17
pubmed: 24612249
Med J Aust. 2014 Sep 15;201(6):326-9
pubmed: 25222455
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):533-546
pubmed: 33965006
J Hepatol. 2019 Jan;70(1):33-39
pubmed: 30367897
Lancet Gastroenterol Hepatol. 2017 May;2(5):325-336
pubmed: 28397696
Addiction. 2017 Jul;112(7):1302-1314
pubmed: 28257600
J Viral Hepat. 2017 Sep;24(9):733-741
pubmed: 28256027
Gut. 2017 Aug;66(8):1507-1515
pubmed: 27196586
J Int AIDS Soc. 2017 Jul 28;20(1):22146
pubmed: 28782335
Lancet Infect Dis. 2018 Dec;18(12):1397-1409
pubmed: 30385157
Clin Infect Dis. 2021 Jul 1;73(1):e69-e78
pubmed: 32421194
Addiction. 2012 Mar;107(3):501-17
pubmed: 21955033
Addiction. 2006 Oct;101(10):1499-508
pubmed: 16968352
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
J Viral Hepat. 2006 Jan;13(1):34-41
pubmed: 16364080
Clin Infect Dis. 2013 Aug;57 Suppl 2:S80-9
pubmed: 23884071
Int J Drug Policy. 2021 Feb;88:102707
pubmed: 32151496
Lancet Gastroenterol Hepatol. 2018 Nov;3(11):754-767
pubmed: 30245064
Lancet. 2016 Apr 2;387(10026):1427-1480
pubmed: 27021149
Addiction. 2009 Aug;104(8):1363-72
pubmed: 19549053
Liver Int. 2023 Mar;43(3):569-579
pubmed: 36305315
Addiction. 2012 Feb;107(2):372-80
pubmed: 21851442
Drug Alcohol Depend. 2009 Nov 1;105(1-2):9-15
pubmed: 19608355
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
Aust N Z J Public Health. 2014 Apr;38(2):165-70
pubmed: 25874282
Lancet. 2019 Oct 26;394(10208):1560-1579
pubmed: 31657732
J Correct Health Care. 2019 Apr;25(2):105-120
pubmed: 31084277